Compare Indonesia Energy Corporation Limited (INDO) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Nuvalent Inc — how do they compare? Indonesia Energy Corporation Limited trades at $3.03 (market cap $46.01M), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 213.2× Indonesia Energy Corporation Limited's market cap, and Nuvalent Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| INDO | NUVL | |
|---|---|---|
Market Cap | $46.01M | $9.81B |
Sector | Energy | Technology |
52-Week High | $6.74 | $123.96 |
52-Week Low | $2.49 | $72.16 |
Enterprise Value | $41.38M | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.
The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
